I

Immunic Therapeutics

Clinical-stage biopharma developing oral autoimmune therapies

Associate Director - Medical Information & Medical Review

Biology & BiotechConfirmed live in the last 24 hours
Full-timeRemote in USA$170k - $210k /yrRemote

About the Job

Requirements

  • A PharmD, MD, PhD, or another relevant advanced scientific or clinical degree with relevant experience.
  • At least six years of progressive experience in Medical Information, Medical Review, Medical Communications, Medical Affairs, or a closely related function within the biotechnology or pharmaceutical industry.
  • Hands-on experience developing and maintaining standard response documents, frequently asked questions, medical information letters, custom scientific responses, or similar Medical Information resources.
  • Experience responding to unsolicited medical and scientific inquiries from healthcare professionals, patients, or other external stakeholders.
  • Experience conducting medical review of promotional and/or non-promotional materials within a cross-functional review process.
  • Scientific writing, literature interpretation, evidence evaluation, and medical review skills, including the ability to produce and evaluate accurate, balanced, evidence-based, and appropriately referenced medical content.
  • Working knowledge of applicable requirements and industry standards governing Medical Information, scientific exchange, responses to unsolicited inquiries, medical review, and pre-approval and promotional communications.
  • Experience partnering effectively with Medical Affairs, Clinical Development, Regulatory Affairs, Legal and Compliance, Pharmacovigilance, Commercial, and external service providers.
  • Ability to exercise independent judgment, identify and manage risk, make well-reasoned recommendations, and escalate issues appropriately.
  • Organizational skills and the ability to manage high-quality scientific deliverables across multiple priorities.
  • Comfort operating in a growing, pre-commercial biotechnology organization where processes are being developed and priorities may evolve.

Responsibilities

  • Build Medical Information capabilities, including response standards, scalable processes, and readiness plans aligned with Medical Affairs priorities, regulatory milestones, and potential launch.
  • Serve as a scientific and clinical resource for internal and external medical inquiries regarding vidofludimus calcium, multiple sclerosis, and Immunic’s broader pipeline.
  • Establish scalable processes for intake, triage, documentation, response, escalation, and analysis of unsolicited medical and scientific inquiries from healthcare professionals, patients, caregivers, and other stakeholders.
  • Develop and maintain accurate, balanced, evidence-based, and appropriately referenced Medical Information resources, including standard response documents, FAQs, medical information letters, and custom responses.
  • Partner with Medical Affairs Operations and external vendors or contact centers to support timely response delivery, training, quality oversight, issue escalation, and performance monitoring.
  • Partner with Pharmacovigilance and Quality to ensure appropriate identification and escalation of adverse events, product complaints, and other reportable information received through Medical Information channels.
  • Analyze inquiry trends, emerging stakeholder needs, and Medical Information insights to inform Medical Affairs planning, congress readiness, field resources, and scientific communication priorities.
  • Serve as a senior medical reviewer for promotional and non-promotional materials across applicable review pathways.
  • Evaluate materials for scientific and clinical accuracy, balance, context, evidence support, and alignment with product development or labeling status.
  • Review the presentation and interpretation of clinical, safety, statistical, mechanistic, and health-outcomes data, including appropriate communication of limitations, uncertainty, and exploratory findings.
  • Provide clear, actionable, risk-based medical review comments and partner cross-functionally to resolve issues and support timely material approval.
  • Help establish Medical Review standards, guidance, documentation practices, escalation pathways, and quality controls that improve consistency, rigor, and review efficiency.
  • Maintain appropriate distinctions among non-promotional scientific communication, responses to unsolicited medical inquiries, corporate communication, and promotional communication.
  • Serve as an internal subject-matter expert for Medical Information and Medical Review, providing strategic recommendations, independent scientific judgment, and practical guidance across the organization.
  • Develop and maintain SOPs, work instructions, templates, content standards, and controlled processes in collaboration with Medical Affairs Operations, Quality, Regulatory Affairs, and Legal and Compliance.
  • Partner with Medical Affairs Operations to define scientific and business requirements for systems, vendors, metrics, and workflows, and provide subject-matter-expert input to support implementation, quality oversight, and continuous improvement.
  • Translate Medical Affairs priorities into clear scientific deliverables and readiness milestones that support late-stage development, regulatory submission, and potential launch.
  • Identify scientific, content-quality, operational, or compliance risks; recommend solutions; and escalate significant issues appropriately.

Desired Qualifications

  • Experience partnering with project-management, operations, vendor, or systems teams.

About the Company

Immunic Therapeutics

Clinical-stage biopharma developing oral autoimmune therapies

Immunic Therapeutics develops oral therapies for chronic inflammatory and autoimmune diseases and is in clinical-stage development. Its lead candidate, vidofludimus calcium (IMU-838), is an oral small molecule that activates the Nurr1 receptor to protect nerve cells and inhibits DHODH to calm overactive immune responses; its pipeline also includes IMU-856, a SIRT6 modulator aimed at restoring intestinal barrier function, with IMU-381 in preclinical GI programs. The company emphasizes oral, small-molecule drugs with dual actions and pursues partnerships or licensing for commercialization rather than relying on near-term product revenue. Its goal is to advance its drug candidates through clinical trials toward commercialization, potentially via collaborations with larger pharma companies.

Company size
51-200
Company stage
IPO
Headquarters
New York City, New York
Founded
2016

Recently Posted Jobs

Explore more opportunities at Immunic Therapeutics

See more jobs